Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $22.5952W HIGH $68.73
Volume
1.65 M
Value Traded
107.81 M
Short % Float
14.17%
-8.59%Week
-21.41%1 Month
-8.04%3 Month
+79.7%6 Month
+141.21%5 Year
-92.41%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
4.91 B
EPS (TTM)
-0.46
P/E Ratio
-
Ent. Value
5.02 B
Total Shares
94.26 M
Float Shares
91.44 M
Insiders
3.00%
Institutions
113.41%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
TVTX Catalyst Timeline
Dated clinical, regulatory and corporate events for Travere Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Travere Therapeutics, Inc.
546Total events
19Upcoming
128Tier-1 (high impact)
2015 to 2037Coverage
Upcoming catalysts 2
Event history 50
▲Subgroup AnalysisFILSPARIApprovedClinical Data
DUPLEX post hoc analysis in FSGS without nephrotic syndrome: 3x higher complete remission, 75% lower kidney failure vs irbesartan
Focal Segmental Glomerulosclerosissource ↗
▲Biomarker DataFILSPARIApprovedClinical Data
PROTECT urinary biomarker analysis: rapid and sustained reductions in macrophage, B-cell, inflammation and complement markers
IgA Nephropathysource ↗
▲Full ResultsFILSPARIApprovedClinical Data
Final SPARTAN data: 75% complete proteinuria remission and eGFR stabilization at 2 years
IgA Nephropathysource ↗
▲Patent GrantedSparsentanApprovedIP / Competition
USPTO issues Notice of Allowance for U.S. Patent Application No. 19/253,120 covering methods of using sparsentan in FSGS
focal segmental glomerulosclerosis (FSGS)source ↗
▲Patent GrantedFILSPARIApprovedIP / Competition
USPTO issues Notice of Allowance for U.S. Patent Application No. 19/253,120 covering methods of using sparsentan in FSGS
focal segmental glomerulosclerosis (FSGS)source ↗
▲Patent GrantedSparsentanApprovedIP / Competition
USPTO granted separate U.S. patent covering certain methods of using sparsentan in IgA nephropathy
IgA nephropathy (IgAN)source ↗
▲Patent GrantedFILSPARIApprovedIP / Competition
USPTO granted separate U.S. patent covering certain methods of using sparsentan in IgA nephropathy
IgA nephropathy (IgAN)source ↗
▲Partnership / LicenseCivorebrutinibCorporate
Closed exclusive licensing and collaboration agreement with Everest Medicines
Primary Membranous Nephropathy and other renal indicationssource ↗
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference 2026 Presentation
▲Partnership / LicenseCivorebrutinibCorporate
Exclusive licensing agreement with Everest Medicines for Civorebrutinib
rare kidney diseasessource ↗
●NDA SubmissionSparsentanApprovedRegulatory Filing
Chugai submitted NDA for sparsentan in Japan
IgA nephropathysource ↗
▲Patent GrantedFILSPARIApprovedIP / Competition
Notice of Allowance from USPTO for patent application directed to methods of using FILSPARI in IgA Nephropathy
IgA Nephropathysource ↗
▼Equity OfferingCorporate
Priced upsized $475.0 million convertible senior notes offering to refinance 2029 convertible notes
◆Oral PresentationFILSPARIApprovedPresentation
Presentation of additional Phase 3 DUPLEX data at NKF Spring Clinical Meeting
FSGSsource ↗
◆Equity OfferingCorporate
Proposed convertible senior notes offering to refinance 2029 convertible notes
▲Patent GrantedFILSPARIApprovedIP / Competition
USPTO issued Notice of Allowance for method-of-use patent
IgA nephropathysource ↗
◆PDUFA DateFILSPARIApprovedRegulatory Filing
New PDUFA target action date for sNDA in FSGS
focal segmental glomerulosclerosis (FSGS)source ↗
▲First Patient DosedPegtibatinaseTrial
First new patient dosed in restarted Phase 3 HARMONY Study
Classical Homocystinuria (HCU)source ↗
◆Enrollment CompleteFILSPARIApprovedTrial
SPARX Study enrollment completion expected
IgAN or FSGS (post-transplant)source ↗
●IP Litigation RulingIP / Competition
Patent settlement with Par and Amneal for Thiola EC generic entry expected April 1, 2026
cystinuriasource ↗
◆PDUFA DateFILSPARIApprovedRegulatory Filing
PDUFA target action date for FILSPARI in FSGS
Focal Segmental Glomerulosclerosis (FSGS)source ↗
◆FDA ApprovalFILSPARIApprovedFDA Decision
Potential FDA approval of FILSPARI for FSGS
Focal Segmental Glomerulosclerosis (FSGS)source ↗
▲Enrollment UpdatePegtibatinaseTrial
Enrollment activities resumed for Phase 3 HARMONY Study of pegtibatinase
Classical Homocystinuria (HCU)source ↗
◆Oral PresentationPresentation
Travere management to present at Guggenheim Emerging Outlook Biotech Summit 2026
●Quarterly UpdateCorporate
Announce complete full year 2025 financial results and corporate update in February 2026
◆Major Amendment SubmittedFILSPARIApprovedRegulatory Filing
FDA determined responses to sNDA review constitute Major Amendment
focal segmental glomerulosclerosis (FSGS)source ↗
◆PDUFA DateFILSPARIApprovedRegulatory Filing
PDUFA target action date for sNDA for FILSPARI in FSGS is January 13, 2026
Focal Segmental Glomerulosclerosissource ↗
◆FDA ApprovalFILSPARIApprovedFDA Decision
Potential FDA approval of FILSPARI for FSGS in 1Q26
FSGSsource ↗
◆Oral PresentationPresentation
Travere Therapeutics to present at 44th Annual J.P. Morgan Healthcare Conference
●Information RequestFILSPARIApprovedRegulatory Filing
Received additional information requests from FDA for FILSPARI sNDA in FSGS
Focal Segmental Glomerulosclerosissource ↗
▲Trial InitiationPegtibatinaseTrial
Pivotal Phase 3 HARMONY Study of pegtibatinase to restart in 1Q 2026
Classical Homocystinuria (HCU)source ↗
▲Product LaunchFILSPARIApprovedPost-Market
Commercial launch of FILSPARI in FSGS, if approved
Focal Segmental Glomerulosclerosis (FSGS)source ↗
▲Enrollment CompleteFILSPARIApprovedTrial
SPARX Study completed enrollment
IgAN/FSGS post-transplantsource ↗
▲Oral PresentationFILSPARIApprovedPresentation
Presented long-term results from DUPLEX OLE at ERA 2026
FSGSsource ↗
◆Oral PresentationFILSPARIApprovedPresentation
Late-breaking analysis from DUPLEX Study to be presented at ASN Kidney Week 2025
FSGSsource ↗
▲Trial InitiationFILSPARIApprovedTrial
SPARX Study evaluating FILSPARI in post-transplant patients with recurrent IgAN or FSGS is open and actively recruiting
IgANsource ↗
▲Manufacturing MilestonePegtibatinaseCMC / Inspection
Successfully manufactured first commercial-scale batches of pegtibatinase
Classical HCUsource ↗
Past FDA Catalysts and PDUFA Decisions
How TVTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-04-14 | FILSPARI (sparsentan) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C53 / 100
Pipeline Score
$638M
Pipeline Value
$2.6B
Commercial Value
Overvalued
Valuation Signal
3
Drugs Scored
0.2x
rNPV / MCap
Top 14%
Small Cap(rank 93 of 658)
Percentile Rank
Travere Therapeutics, Inc. carries a moderate pipeline score (53/100), with $982M risk-adjusted pipeline value, led by Sparsentan in ANCA Associated Vasculitis (Phase 2).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $591.3M x 4.4 = $2.6B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| FILSPARI | $440M | $213M | +106.8% |
| Tiopronin products | $85M | $92M | -7.7% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sparsentan Small moleculeMarketedNCT03762850 | Immunoglobulin A Nephropathy | Phase 3 | ACTIVE NOT_RECRUITING | 478 | Jul 1, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every TVTX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| FILSPARI PriorityAccelerated | IgA nephropathy | Phase 2 | 2026-10-02 | complete proteinuria remission: 75%; e GFR decline: -1.75 mL/min/1.73 m²; chronic e GFR slope: -1.11 mL/min/1.73 m²/year; total e GFR slope: -1.54 mL/min/1.73 m²/year; FSGS complete proteinuria remission: 20%; FSGS partial remission: 79%Read More | Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Heerma PeterOfficer (EVP, CHIEF COMMERCIAL OFFICER) | Option | 8,282 125,348 held | $22.40 | 09/17/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TVTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 3.2 % (33.3 %) | 213.18 M | 3.75 M | -9.41% ( -389.98 K) |
TVTX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TVTX ranks across every disease it competes in
Competitive Position is a premium feature
See how TVTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTVTX News
TVTXTravere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
Travere Therapeutics announced it will present nine new data presentations at ASN Kidney Week 2026, including five oral presentations. The data focuses on the efficacy of FILSPARI® (sparsentan) in treating patients with IgA nephropathy and focal segmental glomerulosclerosis. The final SPARTAN analysis is expected to provide significant insights into the treatment's potential.
Read more →TVTXTravere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis
Travere Therapeutics has received a Notice of Allowance from the USPTO for its patent application concerning methods of using FILSPARI (sparsentan) to treat focal segmental glomerulosclerosis (FSGS). This patent, once issued, will provide U.S. patent protection for specific applications of the drug, potentially strengthening the company's market position in the treatment of kidney diseases.
Read more →TVTXTravere Therapeutics Announces Planned Chief Executive Officer Transition
Travere Therapeutics announced the resignation of CEO Eric Dube, who is stepping down to focus on his health and family. The Board of Directors has appointed Bradley L. Campbell, the former CEO of Amicus Therapeutics, as the new president and CEO. This leadership change reflects the company's commitment to continuity and experienced management.
Read more →TVTXTravere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
Travere Therapeutics, Inc. announced that its management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 24, 2026. The presentation is scheduled for 10:30 a.m. ET and will be available via a live webcast on the company's investor page. A replay of the event will be accessible for 30 days post-presentation.
Read more →TVTXTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics has announced the granting of inducement equity grants to 16 new employees, totaling 56,220 shares of common stock. This decision was made by the Compensation Committee of the Board of Directors on September 10, 2026. The grants are part of the company's strategy to attract and retain talent.
Read more →TVTXTravere Therapeutics to Participate at Upcoming Investor Conferences
Travere Therapeutics, Inc. has announced its participation in several upcoming investor conferences, including Canaccord Genuity's Annual Growth Conference and the Wells Fargo Healthcare Conference. These events are scheduled for August and September 2026. The company's management aims to engage with investors and discuss future prospects.
Read more →TVTX▲ +12%on this news
Travere Therapeutics Reports Second Quarter 2026 Financial Results
Travere Therapeutics has reported its financial results for the second quarter of 2026, highlighting a strong performance that indicates a period of growth for the company. CEO Eric Dube emphasized the disciplined execution of their strategies, which has contributed to their success. The report suggests optimism for both immediate and future prospects.
Read more →TVTXTravere Therapeutics to Report Second Quarter 2026 Financial Results
Travere Therapeutics, Inc. will announce its second quarter 2026 financial results on August 4, 2026, after U.S. market close. A conference call and webcast will follow at 4:30 p.m. ET to discuss these results and provide a business update. Investors can access the details via the company's website.
Read more →TVTXTravere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027
Travere Therapeutics has announced the planned retirement of its Chief Research Officer in 2027. This decision marks a significant transition for the company as it prepares for future leadership changes. The announcement comes as part of the company's ongoing strategic planning efforts.
Read more →TVTXTravere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress
Travere Therapeutics presented long-term open-label extension data from the Phase 3 DUPLEX study at the 63rd European Renal Association Congress. This study highlights the ongoing research into treatments for rare kidney diseases. Additionally, the company announced an exclusive licensing agreement with Everest Medicines for Civorebrutinib, a promising BTK inhibitor.
Read more →TVTXTravere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
Travere Therapeutics has entered into an exclusive licensing agreement with Everest Medicines for Civorebrutinib, a potential best-in-class BTK inhibitor aimed at treating rare kidney diseases. This partnership may enhance the development and commercialization of the drug in targeted markets. Further details about the agreement and its implications for both companies are yet to be disclosed.
Read more →TVTX▲ +7.8%on this news
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy
Travere Therapeutics has received a notice of allowance from the U.S. Patent and Trademark Office for a patent application related to the use of FILSPARI® (sparsentan) in treating IgA nephropathy. This development suggests that the company is making strides in securing intellectual property rights for its therapeutic methods. The patent could enhance the market position of FILSPARI®.
Read more →TVTXEquity Incentive Plan Adopted by the Board of Directors
Travere Therapeutics has adopted a new Equity Incentive Plan, which serves as a successor to previous incentive plans from 2014 and 2015. This plan aims to attract and retain employees, directors, and consultants by offering various stock awards. The Board of Directors will oversee the plan's administration and is empowered to amend the plan as needed. This strategic move is expected to support the company's long-term growth and success.
Read more →TVTXTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 12, 2026
Travere Therapeutics announced the granting of inducement equity grants to four new employees on May 10, 2026. These grants include stock options and restricted stock units (RSUs) totaling 48,800 shares. The stock options have a 10-year term and vest over four years, while the RSUs also vest over four years. This move is in accordance with Nasdaq Listing Rule 5635(c)(4).
Read more →TVTXTravere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
Travere Therapeutics, Inc. has announced a planned offering of $400 million in convertible senior notes due 2032, subject to market conditions. The company intends to utilize part of the proceeds to repurchase a segment of its existing convertible notes due 2029. Additionally, the offering could be expanded by $60 million if underwriters exercise their option for over-allotments. However, uncertainties regarding the repurchase amount and market conditions may impact the overall execution of the offering.
Read more →TVTXTravere Therapeutics to Participate at Upcoming Investor Conferences - May 7, 2026
Travere Therapeutics, Inc. has announced its participation in several upcoming investor conferences, including the BofA Securities 2026 Health Care Conference, the Jefferies Global Healthcare Conference, and the Goldman Sachs 47th Annual Global Healthcare Conference. Presentations will be accessible via live webcasts, with replays available for 30 days. This engagement highlights the company's commitment to the rare disease community.
Read more →TVTXTravere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
Travere Therapeutics has announced an upsized offering of $475 million in convertible senior notes. This move is aimed at refinancing existing convertible notes due in 2029. The offering reflects the company's strategy to manage its debt and optimize its capital structure.
Read more →About Travere Therapeutics, Inc.
Headquarters3611 VALLEY CENTRE DR, SAN DIEGO, CA, 92130
BIOPHARMAWATCH ELITE PLUS
Trade the next TVTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime